(MedPage Today) — The FDA on Wednesday expanded the approval for exagamglogene autotemcel (exa-cel, Casgevy) in severe sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta thalassemia to include children 2 years…
Source link : https://www.medpagetoday.com/hematologyoncology/hematology/122035
Author :
Publish date : 2026-07-02 16:08:00
Copyright for syndicated content belongs to the linked Source.
